MIRUM PHARMACEUTICALS INC (MIRM)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for MIRM
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MIRM | Director | 62 | ["President and Chief Executive Officer of Adverum Biotechnologies, Inc.","Senior Vice President, Head of the Liver Therapeutic Area at Allergan plc","Chief Executive Officer of Tobira Therapeutics, Inc.","Chairman and Chief Executive Officer of Jennerex Biotherapeutics, Inc.","President and Chief Executive Officer of Ocera Therapeutics, Inc.","President and Chief Executive Officer of Auxeris Therapeutics, Inc.","President and Chief Operating Officer of RXCentric.com, Inc.","Chief Medical Officer and Vice President of Corporate Development of MedVantx Inc.","Senior Vice President of the Global Virology Franchise at Dupont Pharmaceuticals/Dupont-Merck","Medical Director for the Virology Group at Hoffman-LaRoche, Ltd.","Board member of CTI BioPharma Corp.","Board member of AtaiBeckley Inc.","Board member of Lycia Therapeutics, Inc.","Board member of Shinobi Therapeutics, Inc.","Board member of Senti Biosciences","Board member of Teal Bio","Medical Degree from the University of Geneva","Doctorate in Medicine from the Geneva Medical School, Switzerland"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Laurent Fischer, M.D., has served as a member of the Board since June 2019. Dr. Fischer served as the President and Chief Executive Officer of Adverum Biotechnologies, Inc., a clinical stage gene therapy company, from June 2020 until its acquisition by Eli Lilly and Company in December 2025. Prior to Adverum, he served as Senior Vice President, Head of the Liver Therapeutic Area at Allergan plc, a pharmaceutical company, from November 2016 to June 2020. Previously, he served as Chief Executive Officer of Tobira Therapeutics, Inc., a public biotechnology company, until its acquisition by Allergan in November 2016. From 2012 to 2014, Dr. Fischer served as Chairman and Chief Executive Officer of Jennerex Biotherapeutics, Inc. Prior to Jennerex, Dr. Fischer was President and Chief Executive Officer of Ocera Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for gastrointestinal and liver diseases, since 2005. Prior to Ocera, Dr. Fischer was President and Chief Executive Officer of life sciences company Auxeris Therapeutics, Inc. from 2003 to 2005, President and Chief Operating Officer of technology company RXCentric.com, Inc. (now part of Allscripts Healthcare Solutions, Inc.) from 1999 to 2000 and Chief Medical Officer and Vice President of Corporate Development of medication management company MedVantx Inc. from 2001 to 2003. Dr. Fischer served as Senior Vice President of the Global Virology Franchise at Dupont Pharmaceuticals/Dupont-Merck from 1997 to 1999. From 1995 to 1997, Dr. Fischer served as Medical Director for the Virology Group at healthcare company Hoffman-LaRoche, Ltd. Dr. Fischer served as Chairman of the board of directors of CTI BioPharma Corp. until its acquisition by SOBI in June 2023 and as a member of the board of directors of Adverum until its acquisition by Eli Lilly and Company in December 2025. Dr. Fischer serves on the board of directors of publicly held AtaiBeckley Inc. (formerly ATAI Life Sciences N.V.), as well as privately held biopharmaceutical companies Lycia Therapeutics, Inc and Shinobi Therapeutics, Inc. Dr. Fischer also served as a member of the board of directors of the then privately held company Senti Biosciences from 2019 until 2020 and privately held company Teal Bio from 2023 to 2025. Dr. Fischer received his Medical Degree from the University of Geneva and his Doctorate in Medicine from the Geneva Medical School, Switzerland. Skills and Qualifications specific to Mirum Pharmaceuticals, Inc.: The Board and Nominating Committee believe that Dr. Fischer s considerable experience as an executive in the pharmaceutical industry and board experience, along with his medical degrees and knowledge of biopharmaceuticals, qualifies him to serve on the Board.